-$0.63 EPS Expected for Immune Design Corp. (IMDZ) This Quarter

Wall Street analysts expect Immune Design Corp. (NASDAQ:IMDZ) to report earnings per share of ($0.63) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Immune Design Corp.’s earnings. The highest EPS estimate is ($0.49) and the lowest is ($0.74). Immune Design Corp. reported earnings of ($0.60) per share in the same quarter last year, which indicates a negative year over year growth rate of 5%. The business is scheduled to issue its next earnings results on Wednesday, November 8th.

On average, analysts expect that Immune Design Corp. will report full year earnings of ($2.28) per share for the current year, with EPS estimates ranging from ($2.54) to ($1.93). For the next financial year, analysts anticipate that the business will report earnings of ($2.24) per share, with EPS estimates ranging from ($2.43) to ($2.07). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Immune Design Corp..

Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. The firm had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.50 million. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%.

Several research firms have commented on IMDZ. ValuEngine raised shares of Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Royal Bank Of Canada started coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price objective for the company. BidaskClub lowered shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Jefferies Group LLC restated a “buy” rating and set a $18.00 price objective on shares of Immune Design Corp. in a research report on Wednesday, June 28th. Finally, Zacks Investment Research upgraded shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $16.33.

In other news, Director Lewis W. Coleman bought 12,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The stock was bought at an average cost of $9.05 per share, for a total transaction of $108,600.00. Following the completion of the acquisition, the director now directly owns 40,000 shares in the company, valued at approximately $362,000. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Lewis W. Coleman bought 10,000 shares of the firm’s stock in a transaction on Monday, July 10th. The stock was purchased at an average price of $9.00 per share, with a total value of $90,000.00. Following the completion of the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $360,000. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 32,000 shares of company stock valued at $295,600. Corporate insiders own 20.70% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in IMDZ. Bank of America Corp DE boosted its holdings in shares of Immune Design Corp. by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after buying an additional 8,418 shares during the period. State of Wisconsin Investment Board purchased a new stake in shares of Immune Design Corp. in the second quarter worth approximately $117,000. Alliancebernstein L.P. purchased a new stake in shares of Immune Design Corp. in the second quarter worth approximately $118,000. Virtu KCG Holdings LLC purchased a new stake in shares of Immune Design Corp. in the second quarter worth approximately $153,000. Finally, Trexquant Investment LP purchased a new stake in shares of Immune Design Corp. in the first quarter worth approximately $183,000. Institutional investors own 51.46% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/10/08/0-63-eps-expected-for-immune-design-corp-imdz-this-quarter.html.

Immune Design Corp. (IMDZ) traded down 4.11% during mid-day trading on Tuesday, reaching $10.50. 133,709 shares of the company were exchanged. The company’s 50 day moving average price is $9.96 and its 200-day moving average price is $8.40. The stock’s market capitalization is $269.00 million. Immune Design Corp. has a 12 month low of $4.50 and a 12 month high of $13.05.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design Corp. (IMDZ)

For more

On average, analysts expect that Immune Design Corp. will report full year earnings of ($2.28) per share for the current year, with EPS estimates ranging from ($2.54) to ($1.93). For the next financial year, analysts anticipate that the business will report earnings of ($2.24) per share, with EPS estimates ranging from ($2.43) to ($2.07). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Immune Design Corp..

Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. The firm had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.50 million. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%.

Several research firms have commented on IMDZ. ValuEngine raised shares of Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Royal Bank Of Canada started coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price objective for the company. BidaskClub lowered shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Jefferies Group LLC restated a “buy” rating and set a $18.00 price objective on shares of Immune Design Corp. in a research report on Wednesday, June 28th. Finally, Zacks Investment Research upgraded shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $16.33.

In other news, Director Lewis W. Coleman bought 12,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The stock was bought at an average cost of $9.05 per share, for a total transaction of $108,600.00. Following the completion of the acquisition, the director now directly owns 40,000 shares in the company, valued at approximately $362,000. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Lewis W. Coleman bought 10,000 shares of the firm’s stock in a transaction on Monday, July 10th. The stock was purchased at an average price of $9.00 per share, with a total value of $90,000.00. Following the completion of the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $360,000. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 32,000 shares of company stock valued at $295,600. Corporate insiders own 20.70% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in IMDZ. Bank of America Corp DE boosted its holdings in shares of Immune Design Corp. by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after buying an additional 8,418 shares during the period. State of Wisconsin Investment Board purchased a new stake in shares of Immune Design Corp. in the second quarter worth approximately $117,000. Alliancebernstein L.P. purchased a new stake in shares of Immune Design Corp. in the second quarter worth approximately $118,000. Virtu KCG Holdings LLC purchased a new stake in shares of Immune Design Corp. in the second quarter worth approximately $153,000. Finally, Trexquant Investment LP purchased a new stake in shares of Immune Design Corp. in the first quarter worth approximately $183,000. Institutional investors own 51.46% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/10/08/0-63-eps-expected-for-immune-design-corp-imdz-this-quarter.html.

Immune Design Corp. (IMDZ) traded down 4.11% during mid-day trading on Tuesday, reaching $10.50. 133,709 shares of the company were exchanged. The company’s 50 day moving average price is $9.96 and its 200-day moving average price is $8.40. The stock’s market capitalization is $269.00 million. Immune Design Corp. has a 12 month low of $4.50 and a 12 month high of $13.05.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design Corp. (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply